YAP1 and melanoma: While a role of YAP1/TAZ for MAPKi resistance has been previously described [19], we extend this knowledge by linking high YAP1/TAZ activity with the distinct MITFlow/AXLhigh melanoma subset across large numbers of melanoma cell lines and patient tumors and identify this phenotype as a potential biomarker predicting response to therapeutic approaches exploiting YAP1/TAZ-associated vulnerabilities in melanoma.